Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $785.1 million.

  • Mirum Pharmaceuticals' Liabilities and Shareholders Equity rose 17.55% to $785.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 9.31%. This contributed to the annual value of $670.8 million for FY2024, which is 3.73% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Liabilities and Shareholders Equity of $785.1 million as of Q3 2025, which was up 8.17% from $725.8 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Liabilities and Shareholders Equity peaked at $785.1 million during Q3 2025, and registered a low of $222.2 million during Q1 2021.
  • Over the past 3 years, Mirum Pharmaceuticals' median Liabilities and Shareholders Equity value was $660.8 million (recorded in 2024), while the average stood at $629.7 million.
  • Data for Mirum Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY soared of 95.47% (in 2024) over the last 5 years.
  • Over the past 5 years, Mirum Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $294.7 million in 2021, then climbed by 19.77% to $352.9 million in 2022, then skyrocketed by 83.23% to $646.6 million in 2023, then climbed by 3.73% to $670.8 million in 2024, then increased by 17.55% to $785.1 million in 2025.
  • Its last three reported values are $785.1 million in Q3 2025, $725.8 million for Q2 2025, and $690.2 million during Q1 2025.